The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.
Also called NCT03944109
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 110 participants
- Registry
-
NCT03944109
-
- Other papers using this trial's data
- PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03944109. Randomized; triple masking; primary purpose treatment. Start 2019-06-20 (actual); primary completion 2020-12-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia
- Condition
- Hyperlipidemia
- Intervention (Drug)
- SHR-1209
- Intervention (Drug)
- Placebo
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct03944109- Content hash
571385b91600e116219139258612d21c65ca4f6b8c379f00a9b0b0a370fec975